Telaglenastat
- Generic Name
- Telaglenastat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C26H24F3N7O3S
- CAS Number
- 1439399-58-2
- Unique Ingredient Identifier
- U6CL98GLP4
- Background
Telaglenastat is under investigation in clinical trial NCT02071862 (Study of the Glutaminase Inhibitor CB-839 in Solid Tumors).
- Associated Conditions
- -
- Associated Therapies
- -
Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-08-30
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 42
- Registration Number
- NCT05521997
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Telaglenastat + Talazoparib In Prostate Cancer
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2021-04-01
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT04824937
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Study to Evaluate the ECG Effects of Telaglenastat in Healthy Adult Subjects
- Conditions
- Interventions
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2021-03-09
- Lead Sponsor
- Calithera Biosciences, Inc
- Target Recruit Count
- 30
- Registration Number
- NCT04607512
- Locations
- 🇬🇧
Celerion, Belfast, Ireland, United Kingdom
Impact of a Histamine H2 Receptor Antagonist (H2RA) on the Pharmacokinetics (PK) of Telaglenastat in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2020-09-07
- Last Posted Date
- 2021-03-09
- Lead Sponsor
- Calithera Biosciences, Inc
- Target Recruit Count
- 22
- Registration Number
- NCT04540965
- Locations
- 🇦🇺
Nucleus Network Brisbane Clinic (formerly Q-Pharm), Brisbane, Queensland, Australia
KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC
- Conditions
- Interventions
- First Posted Date
- 2020-02-11
- Last Posted Date
- 2022-09-21
- Lead Sponsor
- Calithera Biosciences, Inc
- Target Recruit Count
- 40
- Registration Number
- NCT04265534
- Locations
- 🇺🇸
Florida Cancer Specialist - Panhandle (SCRI), Tallahassee, Florida, United States
🇺🇸University of Southern California (USC), Los Angeles, California, United States
🇺🇸St. Joseph Heritage Healthcare, Fullerton, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.